$0.54
5.12% today
Nasdaq, Feb 28, 04:45 pm CET
ISIN
US7027121000
Symbol
PASG
Sector
Industry

Passage Bio Inc Stock price

$0.51
-0.10 16.85% 1M
-0.23 31.28% 6M
-0.06 10.09% YTD
-1.05 67.31% 1Y
-2.81 84.64% 3Y
-21.69 97.70% 5Y
-21.69 97.70% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.00 0.02%
ISIN
US7027121000
Symbol
PASG
Sector
Industry

Key metrics

Market capitalization $31.50m
Enterprise Value $-27.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.47
P/B ratio (TTM) P/B ratio 0.43
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-69.34m
Free Cash Flow (TTM) Free Cash Flow $-59.06m
Cash position $84.83m
EPS (TTM) EPS $-1.17
P/E forward negative
Short interest 3.50%
Show more

Is Passage Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Passage Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Passage Bio Inc forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Passage Bio Inc forecast:

Buy
100%

Financial data from Passage Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.21 3.21
18% 18%
-
-3.21 -3.21
18% 18%
-
- Selling and Administrative Expenses 20 20
46% 46%
-
- Research and Development Expense 43 43
35% 35%
-
-66 -66
38% 38%
-
- Depreciation and Amortization 3.21 3.21
18% 18%
-
EBIT (Operating Income) EBIT -69 -69
37% 37%
-
Net Profit -69 -69
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Passage Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Passage Bio Inc Stock News

Neutral
GlobeNewsWire
2 days ago
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
about 2 months ago
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data
Neutral
GlobeNewsWire
4 months ago
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET.
More Passage Bio Inc News

Company Profile

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Head office United States
CEO William Chou
Employees 58
Founded 2017
Website www.passagebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today